The Ribonucleoside Diphosphate Reductase Large Subunit pipeline drugs market research report outlays comprehensive information on the Ribonucleoside Diphosphate Reductase Large Subunit targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Ribonucleoside Diphosphate Reductase Large Subunit pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Pancreatic Cancer, and Non-Small Cell Lung Cancer. It also reviews key players involved in Ribonucleoside Diphosphate Reductase Large Subunit targeted therapeutics development with respective active and dormant or discontinued products.
The Ribonucleoside Diphosphate Reductase Large Subunit pipeline targets constitutes close to 29 molecules. Out of which, approximately 23 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 1, 2, 8, and 7 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 2 molecule.
Ribonucleoside Diphosphate Reductase Large Subunit overview
Ribonucleoside diphosphate reductase large subunit (RRM1) encodes the large and catalytic subunit of ribonucleotide reductase, an enzyme essential for the conversion of ribonucleotides into deoxyribonucleotides. Deoxyribonucleotides are important for DNA replication during the S phase of the cell cycle as well as multiple DNA repair processes.
For a complete picture of Ribonucleoside Diphosphate Reductase Large Subunit’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
